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Breast imaging reporting and
data system (ACR-BIRADS)Abstract Purpose: The purpose of this study was to evaluate the usefulness of apparent diffusion
coefﬁcient (ADC value) in differentiating between probably benign breast lesions and, suspicious
lesions (ACR-BIRADS categories 3 and 4 respectively).
Patients and methods: Breast lesions meeting study criteria were identiﬁed on dynamic contrast
enhanced (DCE)-MRI examinations in 48 women over the course of the study period for 2 years.
We found 27 (56.2%) of the cases probably benign as their BIRADS category 3 and the remaining
21 (43.7%) cases were category 4. Images were obtained with diffusion sensitizing gradients of 0 and
750 mm2/s. The apparent diffusion coefﬁcient (ADC) was calculated and correlated with the
histological data.
Results: The ADC values recorded a sensitivity of 97.9% and a speciﬁcity of 80%. The positive
predictive value was 95.7% in differentiation between the benign and suspicious breast lesions.
The difference in mean ADC for benign breast lesions (BIRADS-3, 1.45 ± 0.46 · 103 mm2/s),
and suspicious lesions (BIRADS-4, 1.06 ± 0.56 · 103 mm2/s) was statistically signiﬁcant.
Conclusion: Including the ADC diffusion coefﬁcient in the diagnostic work up of patients with
indeterminate breast lesions can help in the differentiation between benign and malignant breast
lesions.
 2015 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier
B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
Magnetic resonance imaging (MRI) is an important tool for
diagnosing breast tumors (1–3). Dynamic contrast-enhanced
breast MR imaging (DCE-MRI) has been reported to havehigh sensitivity for cancer detection, reportedly as high as
88%–100%, but speciﬁcity may be relatively low as 68%–
96% (4–6). However, the moderate speciﬁcity of DCE-MRI
using current morphologic and kinetic enhancement criteria
can present additional challenges (7,8). To minimize false-posi-
tive results without compromising sensitivity, the American
College of Radiology (ACR) introduced the breast Imaging-
Reporting and Data System (BIRADS) MRI lexicon in 2013
(9), which relies on the combined analysis of morphological
appearance and lesion enhancement kinetics and is widely used
Table 1 The breast MRI study lesion characteristics.
Size (longest diameter on DCE-MRI) (No. %)
0.6–1 cm 22(45.8)
1.1–2 cm 17(35.4)
>2 cm 9(18.7)
Shape
Oval 18(37.5)
Round 15(31.2)
Irregular 15(31.2)
Margin
Regular 16(31.2)
Irregular 19(39.5)
Speculated 13(27)
Type of enhancement
Focus 8(16.6)
Non mass 7(14.5)
Mass 33(68.7)
Internal enhancement
Homogenous 10(20)
Heterogeneous 8(16.6)
Rim 3(6.2)
Dark internal septations 4(8.3)
Ring enhancement 1(2)
Branching 5(10)
Time intensity curve type
Type I 18(37.5)
Type II 17(35.4)
Type III 13(27)
BI-RADS assessment
BI-RADS 3 27(56.2)
BI-RADS 4 21(43.7)
ADC value
Benign range more than threshold a 26(54.1)
Malignant range less than thresholda 22(45.8)
Histopathological diagnosis
Benign 24(50)
Invasive carcinoma 15(31.2)
DCIS 8(16.6)
Intra-cystic papillary Ca 1(2)
BIRADS, breast imaging reporting and data system.
a The threshold 1.21 · 103 mm2/s. DCIS, ductal carcinoma
in situ.
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while still debate as to the relative importance of these descrip-
tors as deﬁned in the BIRADS lexicon (10–12). Previous
researches indicated a wide range of cancer yields (0.6–10%)
among probably benign MRI lesions (13–15).
Diffusion-weighted imaging (DWI) has become widely
accepted in body imaging to detect and differentiate benign
from malignant tumors using apparent diffusion coefﬁcient
(ADC) values. Promising ﬁndings from preliminary DWI stud-
ies of the breast have shown signiﬁcantly lower ADC measures
for breast carcinomas than for benign breast lesions or normal
tissue (16–18). The lower ADC in malignancies is primarily
attributed to higher cell density causing increased restriction
of the extracellular matrix and increased fraction of signal
coming from intracellular water (19,20). The aim of this work
was to evaluate the usefulness of ADC value in differentiating
between probably benign breast lesions and, suspicious lesions
(BIRADS categories 3 and 4 respectively).
2. Patients and methods
The study was approved by local ethics committee. It was con-
ducted in the period from June 2012 to June 2014. Dynamic
MRI performed in 48 women patients that were detected on
MRI and assigned ﬁnal MRI BIRADS assessment as category
3 (probably benign), or category 4 (suspicious lesion).
2.1. MRI acquisition
All MRI was performed on a GE Medical System (Signa
Excite; MI, USA), HD 1.5T scanner using a dedicated 4-chan-
nel bilateral breast coil. Each MR examination included a
T2-weighted fast spin echo (FSE) sequence, T1-weighted non
fat-suppressed sequence, T1-weighted DCE-MRI sequence,
and DWI sequence. All scans were acquired in the axial and
sagittal orientation.
– The T2-weighted acquisition was performed using a fat-
suppressed 2D FSE sequence with TR/TE = 6050/85 ms,
32–36 cm ﬁeld of view (FOV), 1.6–2.2 mm slice thickness,
and 320 · 224 matrix.
– A nonfat suppressed T1-weighted 3D fast spoiled gradient
recalled echo sequence was acquired using the same imaging
parameters as for the DCE-MRI sequence described below,
with TR/TE = 6.2/3 ms, ﬂip angle 10, FOV = 32–36 cm,
and 1.6–2.2 mm slice thickness.
– The DCE-MRI protocols performed using a T1-weighted
3D fast spoiled gradient recalled echo sequence with paral-
lel imaging; TR/TE = 6.2/3 ms, ﬂip angle = 10, and
FOV= 32–38 cm scans were performed with 2.2 mm slice
thickness, 350 · 350 matrix, and ﬁve postcontrast acquisi-
tions centered at 90, 180, 270, 360, and 450 s were per-
formed with 1.6 mm slice thickness, 420 · 420 matrix, and
three postcontrast acquisitions centered at 90, 270, and
360 seconds. The contrast administered was 0.1 mmol/kg-
body weight Gd-DTPA (Omniscan, GE).
– DWI was performed using a diffusion-weighted echo
planar imaging (EPI) sequence with spectral spatial fat
suppression and parallel imaging (reduction factor = 2);
TR/TE = 7000/71.5 ms, 3 NEX, matrix = 192 · 192,
bandwidth = 1953 Hz/pixel, FOV= 36 cm, slice thickness =5 mm, gap = 0. Diffusion gradients were applied in six
directions with b= 0 and 750 s/mm2, and the scan time
were 160 s.
– Each lesion was assessed using the American College of
Radiology (ACR) BIRADS Breast MRI Lexicon
incorporating morphologic and kinetic features (9).
Lesion characteristics including size and location, as well
as the BI-RADS assessment and recommendation, were
recorded at the time of interpretation. BIRADS 3 inter-
pretation is most commonly used for rounded, oval, cir-
cumscribed masses with benign kinetics and for focal
areas of non-mass-like enhancement with benign kinetics
(Type I or II). A BIRADS category 4 was assigned if, in
the same setting, a Type III (fast enhancement rate and
wash-out) curve was observed. A BIRADS category 4 was
also assigned in lesions with a suspicious shape (irregular)
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kinetics (21,22). Internal enhancement characteristics were
either homogenous, heterogeneous, stippled, clumped, clus-
tered ring enhancement (9). The diffusion-weighted images
were interpreted at the time of the initial evaluation after
the BIRADS assessments.
– DWI analysis in this study was identiﬁed on DCE-MRI.
Guided by the lesion location on DCE-MRI, a region of
interest (ROI) was deﬁned over the corresponding region
on the b= 750 s/mm2. The ROI was drawn free-hand to
encompass as much of the abnormality as possible, while
avoiding regions of necrosis or cyst by comparing against
the ADC maps and T2-weighted images. The mean DWI
signal intensity was measured for the ROI, and mean
ADC was calculated from the corresponding region on
the ADC map.
– Histopathological correlation: Final diagnosis for all breast
lesions made by correlation of the magnetic resonance DWI
and ADC values and histopathological sections. FNAB was
performed in 30 patients and excision biopsy in 18 patients.Fig. 1 A 25-years old female patient. (A) Axial subtracted dynami
lobulated 1.2 cm enhancing mass in left breast at 12 o’clock. (B) Enhan
(C) DWI in the axial plane, shows no high-intensity of the lesion (a
(ADC) color map reveals not restricted diffusion (the mean ADC=
proved as ﬁbroadenoma.2.2. Statistical analysis
According to the histopathological analysis of the breast
lesions, statistical analysis was done using SPSS (version 17).
The diagnostic accuracy of mean ADC value was evaluated
in terms of sensitivity, speciﬁcity, positive predictive value
(PPV).
The mean ADC value was calculated for the probably
benign lesions (ACR-BIRADS-3) and the suspicious
lesions (ACR-BIRADS-4) and compared by student’s t-test.
P=<0.05 was considered to indicate statistical signiﬁcance.3. Results
Forty-eight female patients, mean age 53.2 years (range 23–
84 years) on pathological basis 24(50%) of the cases were
benign, including 18 ﬁbroadenomas (37.5%), 3 atypical ductal
hyperplasia (6.2%), 3 focal ﬁbrosis (6.2%). The remaining 24
cases were malignant, including 12 invasive ductal carcinomac contrast-enhanced MR image shows rounded, smooth partially
cement kinetics curve Type 1, it was assigned BI-RADS category 3.
rrow) (b-value = 750 s/mm2). (D) Apparent diffusion coefﬁcient
1.63 · 103 mm2/s) (ROI number 2). The lesion pathologically
548 M.H. Abowarda et al.(25%), 8 DCI (16.6%), 3 invasive lobular carcinoma cases
(6.2%) and one intra-cystic papillary Ca (4%).
By conventional MRI we had 27(56.2%) cases category 3
and 21(43.7%) cases category 4. The morphological criteria,
kinematic analysis and BIRADS assessment for the all cases
reported in Table 1.
The mean ADC values were 1.45 ± 0.46 · 103 mm2/s for
the benign lesions (Fig. 1), and 1.06 ± 0.56 · 103 mm2/s for
malignant lesions (Fig. 2), which were signiﬁcantly lower than
the benign (P< 0.005) (Table 2). Also the mean ADC for
DCIS (Fig. 3) was signiﬁcantly lower than benign lesions
(P< 0.05), but not statistically signiﬁcantly vs. invasive malig-
nancies (P= 0.673).
Using cut off value set at 1.21, the ADC sensitivity was
97.8% (45 true positive cases, one false negative case, and
two false positive cases) and 80% and 95.7% for the speciﬁcity
and positive predictive value respectively.
One case cannot be detected in DWI sequence (false nega-
tive); it was 8 mm in size and pathologically proved as IDC.
Two false positive cases were found in our study, their ADCFig. 2 A 34-years old female patient. (A) Axial subtracted image o
upper outer quadrant of right breast, corresponding to suspicious l
anteromedial area of the lesion. (B) Time–signal intensity curve show
diffusion-weighted image shows high signal intensity of the lesion (arr
restricted diffusion (ADC= 0.9 · 103 mm2/s) within the lesion (R
combined MRI protocol because both kinetic analysis and diffusion-we
carcinoma in suit.values within the benign range and pathologically proved as
DCIS (Fig. 3) (1.24 · 103 m2/s), and the other case pathologically
proved as intra-cystic papillary Ca (2.4 · 103 m2/s) (Table 2).4. Discussion
Our study conﬁrms the potential ability of ADC value to dis-
tinguish between the probably benign (BIRADS 3) and suspi-
cious breast lesions (BIRADS 4). A signiﬁcant difference
between the ADC values is probably benign and suspicious
lesions (1.45 · 103 mm2/s vs. 1.06 · 103 mm2/s) (Table 2).
These ﬁnding reported in the literature (21–26).
Moreover in our study, ductal carcinoma in situ (DCIS)
and invasive ductal carcinoma (IDC) did not show signiﬁcant
statistical differences in the ADC values (Table 2). Their ﬁnd-
ings may attributed to the low cellularity in some IDC cases. In
previous literature a direct relationship between cellularity and
ADC values or between cellularity and tumor grade (27). On
the other hand a few authors showed some signiﬁcantf dynamic study shows heterogeneous focal mass enhancement in
esion seen at ultrasound. There are also some enhancements at
s type II curve. Lesion was categorized as BI-RADS 4. (C) Axial
ow). (D) Apparent diffusion coefﬁcient (ADC) color map reveals
OI number 1). Mass was diagnosed as malignant according to
ighted imaging. The lesion pathologically proved as invasive ductal
Table 2 Comparisons of apparent diffusion coefﬁcient (ADC) value according to histopathology.
BI-RADS
assessment (n)
Histopathology (n) Mean ADC value ± SD
(·103 mm2/sec)
P-value
BI-RADS 3 (27) Benign (24) 1.45 ± 0.46 Benign vs. DCIS/
IDC P< 0.005
BI-RADS 4 (21) Invasive ca. (15) 1.06 ± 0.56 Invasive carcinomas vs.
DCIS P= 0.673
DCIS (8) 1.32 ± 0.57 DCIS vs. invasive
carcinomas P= 0.673
Intra-cystic papillary
Ca (1)
2.4 ± 0.34
DCIS = duct carcinoma in situ; ADC= apparent diffusion coefﬁcient, (b value = 0–750 mm2/s). Data are the mean ± SD.
Fig. 3 A 42-years old female patient. (A) Axial subtracted dynamic contrast-enhanced MR image shows rounded, smooth 1 cm
enhancing mass (arrow) in left breast. (B) Enhancement kinetics Type I, it was assigned BI-RADS category 3(benign). (C) DWI in the
axial plan, the lesion not high-intensity. (D) Apparent diffusion coefﬁcient (ADC) color map shows not restricted diffusion with the mean
ADC= 1.24 · 103 mm2/s (ROI number 3). This lesion pathologically proved as DCIS.
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invasive carcinomas, probably caused by different cellular den-
sity that is lower in the in situ forms (28,29).
The two false positive cases found in this study, were diag-
nosed as a benign according to the morphological and kine-
matic MRI picture and their mean ADC values were
1.24 · 103 mm2/s, 2.4 · 103 m2/s, pathologically proved as
DCIS and intra-cystic papillary Ca respectively. In the formercase due to low threshold we used and the latter case
explained due to varying degrees of cystic space within the
tumor. In agreement with Demartini et al. (10), who found
that low vascular tumors like DCIS cannot give the prober
enhancement. Moreover Rubesova et al. (22) found that a
threshold around 1.13 · 103 mm2/s, recorded a highest
sensitivity and speciﬁcity between malignant and benign
lesions.
550 M.H. Abowarda et al.Yabuuchi et al. (25) in their study found that, benign
lesions like the papilloma show papillary growth in a mam-
mary duct; therefore, it contains varying degrees of cystic
space within the tumor. They suppose that the difference of
involved microscopic cystic space might have affected the
ADC value. Additionally, 14 false-positive lesions had
reported in Kul et al. (27), which was proved as atypia, ﬁbro-
cystic changes or ﬁbroadenomatous hyperplasia on
histopathology. All these lesions had to be classiﬁed as BI-
RADS 4 according to the interpretation scheme and these
false-positives reﬂect very well the known pit-falls of breast
MRI.
In the current study using the ADC value improved the dif-
ferentiation between probably and suspicious lesions and we
recorded 97.9%, 80% and 95.7% for the sensitivity, speciﬁcity
and PPV respectively. In agreement with Palle and Balaji (26),
who had reported high sensitivity (97%) for the ADC value in
detection of the malignant breast lesions if added to the con-
ventional MRI.
The DWI sequence in the current study missed one case
only; which was invisible on the dynamic sequence (8 mm
small invasive ductal carcinoma without enhancement).
Similarly Missed case reported in the study of Guo et al.,
DWI was not able to identify a 4-mm DCIS (23).
The sensitivity of DWI in breast lesion detection is inﬂu-
enced by histology and by the large diameter of lesions. In
the study by Belli et al. (30), reported higher sensitivity
(94%) of the DWI in lesion more than 15 mm compared to
sensitivity (65%) in detection smaller lesions. Bogner et al.
(31) stated that the higher ﬁeld strength at (3.0 T) may enable
a DWI acquisition with thinner slices that can better demon-
strate small or diffuse lesions.
Yabuuchi et al. (25), who mentioned that DWI and ADC
may have lower sensitivity than DCE-MRI for detecting breast
cancer. This has been described previously; with 6–37.5% of
malignant breast lesions reportedly not visible on DWI. On
contrary recent researches considered the DWI is the only
sequence able to detect a lesion that was problem solving
sequence in patients with contraindication to contrast media
(28,32).
5. Conclusion
Our ﬁndings suggest that the ADC has important advantages
for use in combined MRI protocols. Lack of speciﬁc malignant
type enhancement cannot exclude malignance so ADC can
give future details about the BIRADS Category 3 and 4.
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